<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409616</url>
  </required_header>
  <id_info>
    <org_study_id>150-CL-035</org_study_id>
    <secondary_id>2007-007036-26</secondary_id>
    <nct_id>NCT01409616</nct_id>
  </id_info>
  <brief_title>To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects</brief_title>
  <official_title>A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate whether ASA, the combination of ASA and
      clopidogrel, and darexaban, which have different effects on blood coagulation, influence each
      other in their effects. Also it will be investigated whether the blood levels of either drug
      are influenced by the presence of the other drug. In addition, the safety and tolerability of
      each drug and the combination of the drugs will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacodynamics of darexaban</measure>
    <time_frame>Baseline and up to 24 hours after six days of dosing of darexaban, ASA, clopidogrel, or a combination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamics of ASA and a combination of ASA and clopidogrel</measure>
    <time_frame>Baseline and up to 24 hours after six days of dosing of darexaban, ASA, clopidogrel, or a combination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASA and the combination of ASA and clopidogrel assessed by plasma concentration</measure>
    <time_frame>Plasma samples are taken until 24 hours after six days of dosing of ASA, a combination of ASA and clopidogrel, or the combination with darexaban</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG), clinical safety laboratory and adverse events</measure>
    <time_frame>6 days for each of the 2 treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pharmacodynamic Interaction</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA, wash-out (w.o.), ASA + darexaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + darexaban, w.o., ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA, w.o., darexaban (double dose) + ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darexaban (double dose) + ASA, w.o., ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darexaban</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_label>Treatment arm F</arm_group_label>
    <other_name>YM150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darexaban (double dose)</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm C</arm_group_label>
    <arm_group_label>Treatment arm D</arm_group_label>
    <arm_group_label>Treatment arm G</arm_group_label>
    <arm_group_label>Treatment arm H</arm_group_label>
    <other_name>YM150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl Salicylic Acid</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_label>Treatment arm C</arm_group_label>
    <arm_group_label>Treatment arm D</arm_group_label>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_label>Treatment arm F</arm_group_label>
    <arm_group_label>Treatment arm G</arm_group_label>
    <arm_group_label>Treatment arm H</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_label>Treatment arm F</arm_group_label>
    <arm_group_label>Treatment arm G</arm_group_label>
    <arm_group_label>Treatment arm H</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 18.5-30.0 kg/m2

          -  Male subjects must be non-fertile, i.e. surgically sterilized or must practice an
             adequate contraceptive method to prevent pregnancies

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to darexaban or ASA or any components of the
             formulation used

          -  Any of the liver function tests (i.e. ALT, AST and bilirubin) above the upper limit of
             normal at repeated measures

          -  Any clinically significant history of any other disease or disorder -
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,
             dermatological, psychiatric or metabolic as judged by the medical investigator

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural and
             herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the
             Clinical Unit, except for occasional use of paracetamol (up to 3 g/day)

          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the
             3 months prior to admission to the Clinical Unit.

          -  Donation of blood or blood products within 3 months prior to admission to the Clinical
             Unit

          -  Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or
             more than 21 units (210 g) of alcohol per week within the 3 months prior to study

          -  Participation in any clinical study within 3 months or participation in more than 3
             clinical studies within 12 months, prior to the expected date of enrolment into the
             study, provided that the clinical study did not entail a biological compound with a
             long terminal half life
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Aster, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=566</url>
    <description>Link to results on JAPIC</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <keyword>darexaban</keyword>
  <keyword>Acetyl Salicylic Acid</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>YM150</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Darexaban</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

